592 related articles for article (PubMed ID: 20679888)
1. Statistical identification of predictors for peripheral neuropathy associated with administration of bortezomib, taxanes, oxaliplatin or vincristine using ordered logistic regression analysis.
Kanbayashi Y; Hosokawa T; Okamoto K; Konishi H; Otsuji E; Yoshikawa T; Takagi T; Taniwaki M
Anticancer Drugs; 2010 Oct; 21(9):877-81. PubMed ID: 20679888
[TBL] [Abstract][Full Text] [Related]
2. [Chemotherapy-induced peripheral neuropathy].
Noguchi E; Maeda Y
Gan To Kagaku Ryoho; 2011 Nov; 38(11):1773-6. PubMed ID: 22083183
[TBL] [Abstract][Full Text] [Related]
3. Oral glutamine for the prevention of chemotherapy-induced peripheral neuropathy.
Amara S
Ann Pharmacother; 2008 Oct; 42(10):1481-5. PubMed ID: 18698011
[TBL] [Abstract][Full Text] [Related]
4. The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity Scale.
Cavaletti G; Frigeni B; Lanzani F; Piatti M; Rota S; Briani C; Zara G; Plasmati R; Pastorelli F; Caraceni A; Pace A; Manicone M; Lissoni A; Colombo N; Bianchi G; Zanna C;
J Peripher Nerv Syst; 2007 Sep; 12(3):210-5. PubMed ID: 17868248
[TBL] [Abstract][Full Text] [Related]
5. Therapy of chemotherapy-induced peripheral neuropathy.
Kaley TJ; Deangelis LM
Br J Haematol; 2009 Apr; 145(1):3-14. PubMed ID: 19170681
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies.
Wolf S; Barton D; Kottschade L; Grothey A; Loprinzi C
Eur J Cancer; 2008 Jul; 44(11):1507-15. PubMed ID: 18571399
[TBL] [Abstract][Full Text] [Related]
7. Hemoglobin, Body Mass Index, and Age as Risk Factors for Paclitaxel- and Oxaliplatin-Induced Peripheral Neuropathy.
Mizrahi D; Park SB; Li T; Timmins HC; Trinh T; Au K; Battaglini E; Wyld D; Henderson RD; Grimison P; Ke H; Geelan-Small P; Marker J; Wall B; Goldstein D
JAMA Netw Open; 2021 Feb; 4(2):e2036695. PubMed ID: 33587134
[TBL] [Abstract][Full Text] [Related]
8. Statistical identification of predictors for paclitaxel-induced peripheral neuropathy in patients with breast or gynaecological cancer.
Kanbayashi Y; Hosokawa T; Kitawaki J; Taguchi T
Anticancer Res; 2013 Mar; 33(3):1153-6. PubMed ID: 23482795
[TBL] [Abstract][Full Text] [Related]
9. Peripheral neuropathy in colorectal cancer survivors: the influence of oxaliplatin administration. Results from the population-based PROFILES registry.
Beijers AJ; Mols F; Tjan-Heijnen VC; Faber CG; van de Poll-Franse LV; Vreugdenhil G
Acta Oncol; 2015 Apr; 54(4):463-9. PubMed ID: 25417732
[TBL] [Abstract][Full Text] [Related]
10. Development and psychometric evaluation of the chemotherapy-induced peripheral neuropathy assessment tool.
Tofthagen CS; McMillan SC; Kip KE
Cancer Nurs; 2011; 34(4):E10-20. PubMed ID: 21242773
[TBL] [Abstract][Full Text] [Related]
11. A randomised, placebo-controlled trial assessing the efficacy of an oral B group vitamin in preventing the development of chemotherapy-induced peripheral neuropathy (CIPN).
Schloss JM; Colosimo M; Airey C; Masci P; Linnane AW; Vitetta L
Support Care Cancer; 2017 Jan; 25(1):195-204. PubMed ID: 27612466
[TBL] [Abstract][Full Text] [Related]
12. Impact of chemotherapy-induced peripheral neuropathy on treatment delivery in nonmetastatic breast cancer.
Speck RM; Sammel MD; Farrar JT; Hennessy S; Mao JJ; Stineman MG; DeMichele A
J Oncol Pract; 2013 Sep; 9(5):e234-40. PubMed ID: 23943894
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapy-induced peripheral neurotoxicity (CIPN): an update.
Argyriou AA; Bruna J; Marmiroli P; Cavaletti G
Crit Rev Oncol Hematol; 2012 Apr; 82(1):51-77. PubMed ID: 21908200
[TBL] [Abstract][Full Text] [Related]
14. Background noise: the experience of chemotherapy-induced peripheral neuropathy.
Bakitas MA
Nurs Res; 2007; 56(5):323-31. PubMed ID: 17846553
[TBL] [Abstract][Full Text] [Related]
15. Neurological monitoring reduces the incidence of bortezomib-induced peripheral neuropathy in multiple myeloma patients.
Velasco R; Petit J; Clapés V; Verdú E; Navarro X; Bruna J
J Peripher Nerv Syst; 2010 Mar; 15(1):17-25. PubMed ID: 20433602
[TBL] [Abstract][Full Text] [Related]
16. Updating your peripheral neuropathy "know-how".
Marrs J; Newton S
Clin J Oncol Nurs; 2003; 7(3):299-303. PubMed ID: 12793336
[TBL] [Abstract][Full Text] [Related]
17. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature.
Badros A; Goloubeva O; Dalal JS; Can I; Thompson J; Rapoport AP; Heyman M; Akpek G; Fenton RG
Cancer; 2007 Sep; 110(5):1042-9. PubMed ID: 17654660
[TBL] [Abstract][Full Text] [Related]
18. A questionnaire survey of physicians' perspectives regarding the assessment of chemotherapy-induced peripheral neuropathy in patients with breast cancer.
Kuroi K; Shimozuma K; Ohashi Y; Takeuchi A; Aranishi T; Morita S; Ohsumi S; Watanabe T; Bain S; Hausheer FH
Jpn J Clin Oncol; 2008 Nov; 38(11):748-54. PubMed ID: 18845520
[TBL] [Abstract][Full Text] [Related]
19. [Chemotherapy-induced peripheral neuropathy: an unresolved issue].
Velasco R; Bruna J
Neurologia; 2010 Mar; 25(2):116-31. PubMed ID: 20487712
[TBL] [Abstract][Full Text] [Related]
20. A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade), in combination with paclitaxel and carboplatin in patients with advanced malignancies.
Ma C; Mandrekar SJ; Alberts SR; Croghan GA; Jatoi A; Reid JM; Hanson LJ; Bruzek L; Tan AD; Pitot HC; Erlichman C; Wright JJ; Adjei AA
Cancer Chemother Pharmacol; 2007 Feb; 59(2):207-15. PubMed ID: 16763792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]